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INTRODUCTION
With a prevalence of 0.32% to 0.64%, diabetes
mellitus is one of the most common endocrine disor-
ders in middle aged dogs, with a predisposition for fe-
male dogs (Guptill et al., 2003; Rand et al., 2004;
Davison et al., 2005; Fall et al., 2007). 
The diagnosis of diabetes mellitus in the dog is re-
latively easy and based on three findings: typical cli-
nical signs (polyuria, polydipsia, weight loss, poly-
phagia), and persistent fasting hyperglycemia and
glycosuria (Plotnick and Greco, 1995a; Fleeman and
Rand, 2001). The combination of persisting fasting hy-
perglycemia and glycosuria is essential for the diag nosis
of diabetes mellitus. A thorough diagnostic work-up is
mandatory to exclude or identify concurrent diseases.
This work-up should minimally include a thorough
physical examination, including oral inspection and
ophthalmic examination, complete blood count, serum
biochemistry profile, including thyroxine and canine
pancreatic lipase immunoreactivity (cPLI) and urina-
lysis with culture. If available, an abdominal ultra-
sound is indicated (Bennet, 2002; Feldman and Nelson,
2004; Monroe, 2009).
Treatment consists of adequate insulin therapy, diet,
regular exercise, ovariohysterectomy in intact bitches,
discontinuation of medication that causes carbohy-
drate-intolerance, and treatment of concurrent inflam-
matory, infectious, hormonal or neoplastic disorders.
An essential part of the therapy is maintaining or
achieving an ideal body weight. The goal is to elimi-
nate the owner-observed clinical signs, provide a good
quality of life and prevent complications such as hypo -
glycemia (Miller, 1995; Fleeman and Rand, 2001;
Feldman and Nelson, 2004). The severity and duration
of hyperglycemia are directly correlated with the clin-
ical signs and the development of complications.
Therefore, it is important to have an adequate insulin
dosage and an appropriate monitoring to fine-tune the
therapy (Feldman and Nelson, 2004; Reusch, 2009). 
Clinical signs are often suggestive and the diagno-
sis in dogs is readily confirmed by simple diagnostic
tests. The true challenge lies in the adequate treatment
and monitoring of the diabetic dog (Bennet, 2002; Van
de Maele, 2005). This review only describes the mon-
itoring of patients with non-ketoacidotic diabetes mel-
litus.
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ABSTRACT
Diabetes mellitus is one of the most common endocrine disorders in the dog. Although diagnostics
are relatively straightforward, treatment and especially adequate long-term monitoring are
challenging. To avoid complications, such as hypoglycemia, weight loss, diabetes ketoacidosis and
urinary tract infections, adequate monitoring is indispensable. In this review different monitoring
tools, such as history and clinical signs, single and serial blood glucose measurements, glycated blood
products, continuous glucose measurements and urine glucose will be evaluated. Because each
monitoring technique has its limitations, the challenge for the veterinarian is to use an adequate
combination of these tools to obtain a good image of the patient’s glycemic status.
SAMENVATTING
Diabetes mellitus is één van de meest voorkomende endocriene aandoeningen bij de hond. De diagnose
kan vrij eenvoudig gesteld worden, maar de behandeling en voornamelijk het toepassen van een gepaste
opvolging vormen een uitdaging. Het goed monitoren is belangrijk om complicaties, zoals hypoglycemie,
gewichtsverlies, diabetes ketoacidose en urineweginfecties, te vermijden. Er bestaan verschillende methoden
om een diabetespatiënt op te volgen: anamnese en lichamelijk onderzoek, éénmalige glucosebepaling,
glucosedagcurves, fructosaminebepaling, geglyceerd hemoglobine, continuë glucosemetingen en glucosurie.
De kunst is om aan de hand van een combinatie van deze technieken een goed beeld te krijgen van de
glycemische status van de patiënt. 
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INITIATION OF INSULIN THERAPY
For the treatment of non-ketoacidotic animals, in-
termediate- or long-acting insulin should be used. The
only drug registered for use in dogs is intermediate-act-
ing insulin (lente: Caninsulin®, MSD, Animal Health).
This type of insulin must be administered with a 40 in-
ternational units (I.U.) syringe. The recommended
starting dosage is 0.25-0.5 I.U./kg of the optimal body
weight twice daily, although most dogs are safely
started on 0.5 I.U./kg twice daily (Fleeman and Rand,
2001; Behrend, 2006). The risk of hypoglycemic
episodes is higher when insulin is administered once
daily, and most dogs need a twice-daily administration
for an adequate glycemic control (Hess and Ward,
2000; Fleeman and Rand, 2001; Davison et al., 2005;
Monroe et al., 2005; Behrend, 2006). 
Newly diagnosed dogs can be closely observed by
the owner at home or can be hospitalized for 24 to 48
hours to evaluate the insulin response. During hospi-
talization, blood glucose concentrations can be meas-
ured at the time of administration and three, six and
nine hours later, while further diagnostic tests are per-
formed. The goal is to identify dogs that might be at
risk for hypoglycemia (Miller, 1995; Fleeman and
Rand, 2001; Behrend, 2006). Patients in which the
glucose concentration drops below 5.6 mmol/l (100
mg/dl) during the first 24 to 48 hours of monitoring,
should be discharged on a dose that is reduced by
25%. Since it takes several days for the diabetic dog to
adjust to the insulin dose or type, the dosage in per-
sistently hyperglycemic dogs is not raised until the
first recheck five to seven days later (Miller, 1995;
Fleeman and Rand, 2001; Monroe et al., 2005;
Behrend, 2006). 
A crucial part in the initiation of therapy is a good
owner communication and education. Dog owners
should be aware of the lifelong commitment, feel com-
fortable administering the insulin, and they should be
taught to recognize possible life-threatening compli-
cations of the disease. It is important to explain to the
owner that it might take at least one to two months to
establish an adequate insulin treatment protocol in un-
complicated diabetes mellitus (Fleeman and Rand,
2001; Bennet, 2002; Mathes, 2002). 
MONITORING OF DIABETIC CONTROL
Poorly controlled diabetic animals are prone to
complications, such as weight loss, diabetes ketoaci-
dosis, urinary tract infections, cataract, etc. The only
way to maintain a long-lasting adequate glycemic con-
trol is to monitor these animals regularly. The most im-
portant criteria are history, clinical signs, serum blood
glucose concentration and serial blood glucose curves,
serum fructosamine levels, serum glycated hemoglobin
concentration, glycosuria and continuous glucose
measurement (Miller, 1995; Bennet, 2002; Wiedmeyer
and DeClue, 2011). When modifying the insulin
dosage, minor adjustments of 10%-25% of the current
insulin dosage are advised (Reusch et al., 2010), be-
cause hyperglycemia is not immediately dangerous
but hypoglycemia may be life-threatening (Miller,
1995). A decrease of 50% is required in case of a So-
mogyi effect (Reusch et al., 2010). A Somogyi effect
is characterized by a rebound hyperglycemia following
a hypoglycemic episode or a rapid decrease of blood
glucose concentration that evokes the release of dia-
betogenic hormones, especially epinephrine and
glucagon, and a direct hypoglycemia-induced stimu-
lation of hepatic glycogenolysis (Feldman and Nelson,
1982).
In the dose determination period, dogs should be
checked every five to seven days. After the appropriate
insulin type, dose and dosing interval have been esta -
blished, the dog should be rechecked one month later. If
there is no relapse of clinical signs or signs of hypo-
glycemia, recheck appointments every three to six
months are advised (Bennet, 2002; Monroe et al., 2005). 
History and physical examination
Technique
Glycemic control can easily be assessed by evalu-
ating the client’s subjective opinion of the severity
and evolution of the clinical signs (polyuria, polydip-
sia, polyphagia, overall health) of his/her dog (Miller,
1995; Wiedmeyer and DeClue, 2011). The veterinarian
should instruct the owner to measure the dog’s water
intake, to document trends in urination frequency, body
weight, activity, appetite and vision changes. During
the first few months, weekly calls from the owners
should be encouraged and ideally they should keep a
logbook to help with the long-term monitoring (Ben-
net, 2002; Van de Maele, 2005). The most reliable
clinical parameters are the absence or presence of
polyuria, polydipsia, lethargy and weakness. The fol-
low-up of body weight in the medical record is of the
utmost importance. Unexpected weight loss and the
presence of ketonuria are indicators of poor control.
However, their absence does not rule out a poor con-
trol. The presence of hepatomegaly or cataract is a
poor indicator of the current glycemic control (Briggs
et al., 2000).
Pros and cons
The history, combined with the physical examina-
tion findings and the evolution of body weight, appears
to be a reliable indication for the glycemic control
(Briggs et al., 2000). Most of the animals with glucose
concentrations between 5.6 and 13.9 mmol/l (100 – 250
mg/dl) are relatively asymptomatic, and the owner is
satisfied with the treatment results (Nelson and Couto,
2009). Although the history is an easy and fast way to
determine the effectiveness of insulin treatment, it is
subjective and its reliability depends largely on the
observational skills of the owner (Briggs et al., 2000;
Wiedmeyer and DeClue, 2011). The subjectivity of
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this evaluation is decreased when combined with other,
more objective monitoring tools discussed further
(Miller, 1995; Briggs et al., 2000; Feldman and Nelson,
2004). If the history and physical examination are in-
dicative of poor glycemic control, further diagnostics
are warranted to define the cause of the poor control
(Plotnick and Greco, 1995b; Briggs et al., 2000). Ben-
net (2002) states that the insulin dosage can be in-
creased in patients with obvious signs of polyuria,
polydipsia and polyphagia without further diagnos-
tics. However, this is generally not advised and possi-
bly dangerous, since the clinical signs may also be at-
tributable to the hyperglycemic phase of the Somogyi
phenomenon (Feldman and Nelson, 1982). In patients
that have no clinical signs, a stable body weight and a
normal physical examination, serial blood glucose
measurements are probably not necessary. This is es-
pecially true if morning pretreatment glucose is be-
tween 5.6 and 16.7 mmol/l (100 – 300 mg/dl) (Briggs
et al., 2000). In other words, history and physical ex-
amination findings that can easily be monitored at
home by the client can be used to assist clinical judg-
ments, and are a good indicator of poor glycemic con-
trol. Nevertheless, more objective criteria should be
evaluated before adjusting the insulin therapy (Briggs
et al., 2000; Wiedmeyer and DeClue, 2011).
Single blood glucose measurement
Technique 
A single glucose measurement can be performed
with a point-of-care analyzer or a portable blood glucose
measurement (PBGM) device. Blood can not only be
collected through standard venipuncture of the vena
jugularis or vena cephalica, but also by puncturing the
ear veins (Wess and Reusch, 2000; Bennet, 2002). 
Pros and cons
A single blood glucose measurement (BGM) is only
useful if hypoglycemia is identified (< 3.3 mmol/l (60
mg/dl)), because in that case the insulin dosage should
be decreased. One elevated BGM is not enough to con-
firm poor glycemic control or to evaluate the effect of
a given type and dose of insulin (Nelson and Couto,
2009). An exception can be made for dogs with a his-
tory, physical examination and fructosamine concen-
tration indicating good to excellent control. If the pre-
treatment BGM is between 10 and 15 mmol/l (180 –
270 mg/dl), a serial measurement is probably not ne-
cessary and good control can be presumed (Reusch,
2009). Evaluating a BGM alongside a fructosamine or
glycated hemoglobin concentration can help with its in-
terpretation. When interpreting a BGM, it is important
to know the timing of the dog’s last meal and the insu-
lin dose. Bennet (2002) states that a single measurement
may be informative when taken at the time of the nadir,
determined during a previous blood glucose curve
(BGC). However, this is discouraged by Fleeman and
Rand (2003), who found a large day-to-day varia bility
in timing of the nadir. Furthermore, a single BGM is
highly influenced by stress, excitement, fear or aggres-
siveness, which may lead to an unreliable measurement
(Bennet, 2002; Fleeman and Rand, 2003, Nelson and
Couto, 2009). 
Fructosamine and glycated hemoglobin
Technique
Fructosamine and glycated hemoglobin are formed
by an irreversible, non-enzymatic and non-insulin de-
pendent binding of glucose to serum proteins or hemo -
globin, respectively (Armbruster, 1987; Bunn et al.,
1976).
Serum fructosamine concentrations reflect the ave-
 rage blood glucose concentration over a period of one
to three weeks in dogs (Kawamoto et al, 1992; Reusch
et al., 1993; Loste and Marca, 2001). The fructosamine
concentration increases parallel with glucose levels,
and is far more reliable than a single BGM, since it is not
influenced by acute changes due to stress or excite-
ment (Reusch et al., 1993; Marca et al., 2000; Loste and
Marca, 2001; Bennet, 2002). Fructosamine is decreased
by hypoproteinemia, hypoalbuminemia, hyperlipide-
mia and azotemia in dogs, and is unreliable in these si-
tuations (Kawamoto, 1992; Reusch and Haberer, 2001).
Additionally, fructosamine levels should be interpreted
with caution in hypothyroid dogs, since they might be
elevated due to a reduced protein turnover (Reusch et al.,
2002).
Some authors advise to freeze the sample until as-
sayed (Nelson and Couto, 2009). However, this is re-
futed by Jensen (1992), who proved that 5-day storage
at 25°C does not significantly affect the serum fructo-
samine concentration. The reference interval is labo-
ratory dependent, but is usually around 200-360 µmol/l
(Reusch, 2009). An overview of the interpretation is gi-
ven in Table 1 (for correct interpretation, laboratory
specific reference intervals should be used). When in-
terpreting the laboratory result, it should be kept in
mind that normoglycemia is not the goal of insulin the-
rapy. Serum fructosamine may therefore be higher in
diabetic dogs than in normal, healthy dogs that are used
to make up reference intervals (Feldman and Nelson,
2004; Reusch, 2009).
Table 1. Interpretation of the fructosamine concentra-
tion in diabetic dogs (adapted from Nelson and Couto,
2009).
Degree of control Range of
fructosamine levels
Excellent control 350-400 µmol/l
Good control 400-450 µmol/l
Fair control 450-500 µmol/l
Poor control >500 µmol/l
Prolonged hypoglycemia <300 µmol/l
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The glycosylated hemoglobin (GHb) concentration
reflects the mean glucose concentration over a period
of 10 to 14 weeks in dogs, depending on the life span
of red blood cells (Reusch, 2009). As for fructosamine,
it is not affected by acute changes and is directly pro-
portional to the glucose level. Anemia will falsely
lower the value (Marca et al., 2000; Feldman and Nel-
son, 2004). GHb is not commonly used in veterinary
medicine, due to the large variation in assays and con-
sequently, the wide variation of reference values be-
tween laboratories. Moreover, many assays have not
been validated for canine patients (Reusch, 2009). 
Pros and cons 
Serum fructosamine concentration can be used as a
screening test for diabetes mellitus, in the routine eva-
luation of the diabetic dog: 1. when there are discre-
pancies between history, physical examination and se-
rial blood glucose concentrations, 2. to rule out the
effect of stress or excitement on the glucose concen-
tration, 3. to evaluate the response to an insulin dosage
change (Jensen, 1994; Jensen, 1995; Loste and Marca,
2001; Feldman and Nelson, 2004). In early diagnosed
patients, the fructosamine levels may be normal due to
insufficient duration or degree of the hyperglycemia
(Reusch and Haberer, 2001). Discrepancies between
fructosamine levels on the one hand and clinical signs
and blood glucose on the other hand have been obser-
ved. In those cases, the veterinarian should rely on the
clinical signs to judge the glycemic control (Briggs et
al., 2000; Reusch, 2009). Serum fructosamine may be
within normal ranges when there are periods of hyper-
and hypoglycemia, resulting in a mean glucose con-
centration within or near the normal range. Elevated
fructosamine concentrations indicate insufficient gly-
cemic control, but may be attributable to an inade-
quate insulin dosage, owner non-compliance or ex-
treme fluctuations in serum glucose levels (e.g.
Somogyi phenomenon). Therefore, a fructosamine re-
sult does not allow to differentiate between causes of
poor glycemic control and does not allow adequate the-
rapy adjustments. Conversely, serum concentrations in
the lower half or below the reference interval may in-
dicate significant periods of hypoglycemia (Bennet,
2002; Feldman and Nelson, 2004). Furthermore, serum
fructosamine gives no information about the nadir or
acute blood glucose changes in response to insulin ad-
ministration. The soundest approach is to use abnormal
serum fructosamine concentrations as an indication of
inadequate glycemic control. Subsequently, the BGC
can be performed to determine which changes should
be made to the insulin protocol (Behrend, 2006; Wied-
meyer and DeClue, 2011). 
Since GHb reflects the mean glucose concentration
of the previous two to three months, it is not an ap-
propriate parameter in animals that still undergo regu-
lar changes the insulin dosage, but it can be used in the
follow-up of animals with long-term good control.
Elevated concentrations are an indication of poor con-
trol, and further diagnostics such as the BGC are
needed (Kawamoto et al., 1992; Bennet, 2002). In ve-
terinary medicine, serum fructosamine measurements
are commercially more readily available and more
practical to use (Feldman and Nelson, 2004; Wied-
meyer and DeClue, 2011). GHb is more sensitive for
the detection of hypoglycemia than fructosamine
(Loste and Marca, 2001). 
Serial blood glucose curve
Technique
When serial glucose measurements are performed
while the animal is hospitalized, the normal daily rou-
tine of feeding and insulin should be followed. If the
dog refuses to eat while hospitalized, the owner can
feed the dog at home and bring the animal to the prac-
tice right after, since inappetence may seriously influ-
ence the results (Fleeman and Rand, 2001; Feldman
and Nelson, 2004). To exclude problems with injection
proficiency, the owner can administer the insulin while
supervised in the practice (Bennet, 2002; Reusch,
2009). The first blood sample should be taken imme-
diately before feeding and injection, or within the hour
after doing so (Reusch, 2009). Samples should be ta-
ken every one to two hours throughout the day, de-
pending on the type of insulin. In total, monitoring for
12 hours should be sufficient for intermediate acting ty-
pes of insulin. Twenty-four hours may be required for
long-acting insulin types. Longer-acting insulin types
tend to have a less predictable peak action (Fleeman
and Rand, 2001; Feldman and Nelson, 2004).
Sample collection can be done through standard
venipuncture or by an ear prick (Wess and Reusch,
2000; Fleeman and Rand, 2001; Bennet, 2002). Blood
glucose concentrations are typically determined by a
PBGM device or a point-of-care glucose analyzer
(Bennet, 2002; Feldman and Nelson, 2004). Results
obtained with the PBGM device generally underesti-
mate the actual glucose level, depending on the device
and the degree of glycemia (Wess and Reusch, 2000;
Cohn et al., 2000). It is important to consider this er-
ror to avoid overdiagnosing hypoglycemia or avoid the
misperception that glycemic control is better than it ac-
tually is (Wess and Reusch, 2000; Feldman and Nelson,
2004). 
In the initial regulation of the diabetic dog, weekly
BGC’s are mandatory to reach an acceptable glycemic
control. In addition, curves are necessary to re-establish
glycemic control in dogs with clinical signs of hyper-
glycemia. History, physical examination, body weight
and serum fructosamine determine the necessity of a
curve (Bennet, 2002; Behrend, 2006). 
The reliability of this technique is patient depen dent
since anorexia, inactivity, stress, agitation and aggres-
sion may influence the glucose level. This should be
taken into account when interpreting the BGC. It is im-
portant to avoid stress during these check-ups and to
prevent aversion towards the veterinarian and his ac-
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tions, thereby improving the chances of obtaining re-
liable blood glucose results (Feldman and Nelson,
2004). 
Interpretation
Ideally, the blood glucose concentrations should
range between 6 and 14 mmol/l (100 – 250 mg/dl)
throughout day and night. In most dogs, the highest
concentrations occur at the time of each insulin injec-
tion. Ideally, the BGC should appear as an inverted bell,
with the nadir in the middle (Miller, 1995; Behrend,
2006) (Figure 1). 
Three important parameters need to be evaluated
consecutively: 1. insulin effectiveness, 2. glucose nadir
and 3. duration of effect. The effectiveness is the dif-
ference between the maximal and minimal glucose
concentration. This difference has to be interpreted in
light of the highest glucose concentration and the in-
sulin dosage (e.g. a small difference may be acceptable
if the insulin dosage or the highest glucose concentra-
tion is low, but not if the dosage or the maximal con-
centration is high) (Miller, 1995; Nelson and Couto,
2009). The nadir should be between 4.4 and 8.3 mmol/l
(80 – 150 mg/dl). If this value is lower or higher, the
dosage should be decreased or increased, respectively
(Nelson and Couto, 2009). A low nadir may be due to
insulin overdosage, excessive overlap of insulin action,
insufficient food intake or excessive exercise. Under-
lying causes of a high nadir may be insulin under-
dosage, technical problems with insulin administration,
the counterregulatory phase of the Somogyi phenom-
enon, stress, hyperglycemia or insulin resistance
(Reusch, 2009). The duration of effect is the time from
the injection until the glucose concentration rises above
13.9 – 15 mmol/l (250 – 270 mg/dl). This should be
around 10 to 14 hours. If the duration is too short,
switching to longer acting insulin every 12 hours or
shorter acting insulin three times a day, is recom-
mended. If the effect lasts longer than 14 hours, a
shorter acting insulin or a once-daily administration can
be considered. The duration may be falsely decreased
if the nadir is less than 4.4 mmol/l (80 mg/dl) or if
blood glucose declined rapidly, due to the possible
Somogyi effect (Miller, 1995; Behrend, 2006; Nelson
and Couto, 2009; Reusch, 2009). An overview of the
interpretation is given in Figure 2.
Figure 1. Blood glucose concentration curves obtained from three diabetic dogs treated with a twice-daily insulin pro-
tocol, illustrating poor control, good control and the Somogyi phenomenon. 
Poor control: the insulin is not effective in lowering the blood glucose concentration; the blood glucose concentration
stays above 11 mmol/l.
Good control: the insulin is effective in lowering the blood glucose concentration, the nadir is 6 mmol/l, and the dura-
tion of the effect is around 9 to 10 hours. 
Somogyi effect: the insulin is effective in lowering the blood glucose concentration, but the nadir is 3 mmol/l; this hypo-
 glycemic episode is rapidly followed by a rebound hyperglycemia
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Pros and cons
The evaluation of the BGC demonstrates the phar-
macology of the insulin in a particular dog. It provides
knowledge of the adequacy of the insulin dosage, the
duration of the insulin effect, the nadir, the client com-
pliance, injection timing, insulin resistance and client
injection proficiency. Unlike the previously described
monitoring techniques, the evaluation of the BGC ena-
bles the veterinarian to identify the cause of poor gly-
cemic control. BGC’s are a good tool for fine-tuning the
insulin therapy in dogs (Bennet, 2002; Van de Maele,
2005; Behrend, 2006; Wiedmeyer and DeClue, 2011). 
The blood glucose curve is easy to perform, accu-
rate, and is considered to be the gold standard. Unfor-
tunately, hospitalization, restraint, repeated venipunc-
tures or ear pricks do not only make this a time
consuming and expensive technique, they also influ-
ence the patient’s blood glucose concentration (Miller,
1995; Wess and Reusch, 2000; Wiedmeyer and De-
Clue, 2011). For these reasons, BGC’s are sometimes
difficult to perform, hard to interpret and might not al-
ways correlate with the real-life glycemic control
(Wiedmeyer and DeClue, 2011). Fleeman and Rand
(2003) demonstrated a marked day-to-day variability in
BGC’s of two consecutive days. This is probably at-
tributable to fluctuations in the postprandial glycemic
response, the variable absorption rate from the injection
site, an inherent error with the dosing syringe, variation
in activity or whereabouts and variable sensitivity to in-
sulin. This finding has important clinical implications,
especially in well-controlled dogs, leading to the as-
sumption that additional indicators for glycemic con-
trol should be evaluated when adjusting the insulin pro-
tocol. When interpreting a curve, the history, clinical
signs and other parameters such as fructosamine should
always be considered in the evaluation of the effi-
ciency of glycemic control over a certain period of time
(Miller, 1995; Hess and Ward, 2000; Bennet, 2002;
Fleeman and Rand, 2003). Another problem is the re-
liability of the PBGM device, which depends on the an-
alytical performance of the device, the quality of the
test strip and the proficiency of the operator (American
Diabetes Association, 1996; Cohn et al., 2000).
In the past, serial blood glucose measurements were
always performed in the veterinary practice or the hos-
pital, but for some years now, home monitoring has
gained popularity. Home monitoring of blood glucose
concentration and continuous glucose monitoring are
good alternatives to avoid complications that can oc-
cur with BGC’s performed at the hospital (Fleeman and
Rand, 2001; Davison et al., 2003; Wiedmeyer and De-
Clue, 2011).
Home monitoring of blood glucose concentration
Technique
Capillary or venous blood can easily be obtained
from the ear with a lancet designed for finger-pricks in
humans or a small-gauge needle. Subsequently, the
glucose measurement is done with a PBGM device
(Casella et al., 2003; Van de Maele, 2005). Pre-warm-
ing of the ear with a hair dryer improves the blood drop
formation (Wess and Reusch, 2000). It is important that
the owner feels comfortable with the procedure. There-
fore, a gradual introduction to the idea of home mon-
itoring, a good explanation of the technique and the
possibility to contact the veterinarian if problems oc-
Figure 2. Algorithm for interpreting results of a blood glucose concentration curve (adapted from Nelson and Couto, 2009). 
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cur, are key to a successful outcome (Casella et al.,
2003; Reusch, 2009). 
Pros and cons
In hospitalized dogs, there is an obvious influence
of stress, excitement and aggression on the BGC,
which can largely be prevented by performing the
BGC at home. An important problem within the hos-
pital environment is the lack of appetite, which can ef-
fectively be avoided by using home monitoring. A
study of Casella et al. (2003) showed that therapy ad-
justments based on hospital curves differed from those
based on home curves in 42% of the cases, but only in
3% they would have been reversed (increase versus de-
crease of the insulin dosage). Major difficulties which
owners may encounter are: resistance of the pet, the
need for a second person, the need for multiple punc-
tures (due to technical problems or pet resistance), in-
sufficient blood drop, inadequate absorption of the
blood drop, the need for an additional strip, problems
with the PBGM device and a visible puncture site af-
terwards (Casella et al., 2003; Van de Maele, 2005).
Studies have shown that the majority of pet owners are
willing and able to perform curves and that they are
pleased with the result, provided that they are moti-
vated and initially receive an adequate explanation
(Casella et al., 2003; Van de Maele, 2005). Long-term
owner compliance is good, and although they should be
warned not to adjust the insulin therapy without vet-
erinary advice, only a minority of owners change the
therapy independently (Reusch, 2009; Wiedmeyer and
DeClue, 2011). A disadvantage is the day-to-day vari-
ability of BGC’s performed at home, which can how-
ever be minimized by performing two home BGC’s on
consecutive days (Fleeman and Rand, 2003; Reusch,
2009). 
Continuous glucose monitoring 
Technique
Continuous glucose measurement systems measure
the glucose concentration in the subcutaneous intersti-
tial fluid using subcutaneous probes or wires. The pre-
ferred localization is the lateral thoracic region (Figure
3). An enzymatic reaction generates an electrical sig-
nal proportional to the interstitial glucose concentration
(Wiedmeyer et al., 2003; Affenzeller et al., 2010). This
technique has been used in human medicine for some
years, and has now been adjusted for veterinary use
(Gross and Mastrototaro, 2000; Wiedmeyer et al.,
2003). Measurements take place every three to five
minutes, depending on the device, and the system can
remain in place for several days. Some devices have
real time view of the glucose data, and results can be
downloaded from the recording device, providing a de-
tailed glucose profile over a period of time (Wied-
meyer et al., 2003; Wiedmeyer and DeClue, 2008; Af-
fenzeller et al., 2010).
Pros and cons
Continuous glucose monitoring is a good alternative
to BGC’s. The interstitial fluid glucose concentration
correlates well with the blood glucose concentration
and the device records even abrupt changes in glucose
concentration with a slight delay of five to twelve min-
utes (Gross and Mastrototaro, 2000; Davison et al.,
2003; Wiedmeyer et al., 2003). Digital filters may cor-
rect for this delay, but Rebrin et al. (1999) state that this
is not necessary for slower glucose dynamic changes.
Since the subcutaneous probe remains in place, multi-
ple punctures are avoided, the technique is minimally
invasive, and hospitalization and restraint are not nec-
essary. Continuous assessments of the blood glucose
concentration are obtained, thus facilitating the detec-
tion of brief hypoglycemic periods and overnight mon-
itoring. Consequently, a global image of the dog’s
glycemic status is generated during its normal day-to-
day routine, so sound adjustments in the insulin ther-
apy can be made if necessary (Davison et al., 2003;
Wiedmeyer et al., 2003; Wiedmeyer and DeClue, 2008;
Fleeman, 2011). As the system may remain in place for
up to three days, it can take into account the day-to-day
variability noted with BGC’s (Fleeman and Rand,
2003; DeClue et al., 2004). Generally, the system is
well tolerated, and the removal of the device only
causes mild discomfort (Wiedmeyer et al., 2003; Af-
fenzeller et al., 2011). 
A mild drawback of this technique is the need for a
1-hour initialization period and calibration requiring
blood samples three times a day. Depending on the de-
vice, these blood glucose measurements have to be
evenly spaced in time or not, but the first sample has
to be taken as soon as the initialization period is over.
Calibration measurements can be performed with a
PBGM device by the owner or by the veterinarian
(DeClue et al., 2004). Other disadvantages of this sys-
tem include high purchase costs, possible detachment
from the skin, foreign body reaction, calibration errors
and the device’s limited range (e.g. Guardian Real-
Time; Medtronic: 2.2 - 22 mmol/l). The last makes this
technique less reliable in animals with marked hyper-
or hypoglycemia, which are unfortunately the patients
that would benefit most from continuous monitoring.
Figure 3. Diabetic dog wearing a continuous glucose
monitoring device (Guardian Real-Time; Medtronic).
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Furthermore, calibration is impossible when the glu-
cose concentration is beyond this range (Davison et al.,
2003; Wiedmeyer et al., 2003; DeClue et al., 2004;
Wiedmeyer and DeClue, 2008). These disadvantages
may cause difficulties when the animals are not hos-
pitalized. However, the initialization period, the need
for calibration and the range are device dependent. A
new system based on microdialysis (GlucoDay; Menar-
ini Diagnostics) has been tested. It requires only two
calibration sessions (soon after attachment and right be-
fore removal), and the glucose concentration range is
wider (1.1 – 33.3 mmol/l). Disadvantages are the sys-
tem’s relatively large size, the fact that there is no
wireless system available, and that it does not provide
real-time display of the glucose concentration (Affen-
zeller et al., 2010; Fleeman, 2011). Davison et al.
(2003) noted that there are discrepancies between blood
and interstitial glucose concentrations measured by a
classical device (MiniMed; Medtronic) one to three
hours after the meal, but overall, the correlation is
good, although the interstitial values are generally
slightly lower. The devices are designed for human use
and the error signal is not particularly audible from a
distance. This may result in a loss of data when the er-
ror is not noted in time (Davison et al., 2003). 
Glycosuria
Technique
Urine can readily be obtained in dogs; if necessary,
a long-handled cup or a flat pie pan may facilitate the
collection (Miller, 1995). Glycosuria (and ketonuria)
can easily be determined semi-quantitatively with a dip
stick. In a well-controlled diabetic dog, the absence of
glycosuria alternates with periods of glycosuria
throughout the day. If used, the interpretation should be
based on multiple measurements throughout the day or
measurements made over three consecutive days to
monitor the trend (Bennet, 2002; Feldman and Nelson,
2004, Reusch, 2009). Bennet (2002) advises daily
checks during the initial treatment period, and once the
animal is well regulated, this can be reduced to once
weekly (Fleeman and Rand, 2001). 
Pros and cons
Urine glucose measurement can be used in dia-
betic bitches after ovariohysterectomy to evaluate
whether insulin therapy remains necessary. Moreover,
it may be helpful in dogs with recurring hypoglycemia
(or ketosis) (Feldman and Nelson, 2004). The urine
glucose concentration cannot be used alone to adjust
the insulin dosage (Miller, 1995; Bennet, 2002; Mon-
roe, 2009). Consistent severe glycosuria, the presence
of ketones or persistent absence of glycosuria demon-
strate the need for blood glucose evaluation. It is im-
portant to consider that an insulin overdosage may re-
sult in the Somogyi phenomenon and in a persistent
hyperglycemia and glycosuria for 24 to 72 hours
(Miller, 1995; Nelson and Feldman, 2004). Increasing
the insulin dosage based on glycosuria in the latter sit-
uation will only result in more severe hypoglycemia,
more pronounced rebound hyperglycemia and even
worse glycemic control. Owners may not adjust the in-
sulin dose based on the result of morning urine glucose,
except for a dose decrease for dogs that have recurrent
episodes of hypoglycemia and permanent absence of
glycosuria (Bennet, 2002; Nelson and Couto, 2009).
Urine glucose measurement is an easy and inexpensive
alternative to the home BGC, but it does not provide
detailed information about the blood glucose concen-
tration, nor does it determine the nature of poor
glycemic control (Schaer, 2001, Wiedmeyer and De-
Clue, 2011). Important shortcomings are that 1. the test
is semi-quantitative ; 2. urine collection is not always
easy; 3. a negative test does not differentiate between
hypo-, normo- or mild hyperglycemia; 4. hydration
status and urine concentration affect the result;  5. it
does not reflect the blood glucose level at any given
time, since the bladder stores urine (Schaer, 2001;
Reusch, 2009). Urine glucose measurement serves as
an alert system for problems in the glycemic control,
but this method should be combined with an evaluation
of the clinical signs, the BGC and serum fructosamine
concentration before adjusting the therapy (Miller,
1995; Schaer, 2001).
CONCLUSION
Adequate monitoring of the diabetic patient is a chal-
lenge. Different monitoring techniques are available,
but each of the described techniques has its li mitations
when used individually. Sound insulin therapy changes
should be based on a combination of diagnostic tests and
the evaluation of the animal’s clinical status. 
Owners play a crucial role in the treatment and
monitoring of the diabetic dog. They should continu-
ously evaluate their pets for recurrence of clinical signs
or complications. After the initiation of the insulin
therapy, the animal should be evaluated weekly by a
veterinarian for approximately one month. At these
controls, body weight evolution and clinical signs are
evaluated, and the BGC is performed. The serum fruc-
tosamine concentration can be evaluated three weeks
to one month after the initiation (or adjustment) of the
insulin therapy. When glycemic control is adequate, pa-
tients should be evaluated every 3 to 6 months. At
these check-ups, history, physical examination, body
weight and serum fructosamine are evaluated. When
poor control is suspected, the BGC is performed to
identify the problem and adjust the therapy accord-
ingly. Since diabetic animals, and especially those with
poor control, are at risk for urinary tract infections, a
urine culture should be performed once or twice a
year.
Single blood glucose measurements are not useful
in long-term monitoring and can only be used to mo-
dify the insulin therapy if hypoglycemia is detected.
Owners can determine the urine glucose concentration
Vlaams Diergeneeskundig Tijdschrift, 2012, 81 203
once weekly, which can serve as an alert system for the
need for further evaluation of the glycemic control. Se-
rum fructosamine represents a reflection of the average
blood glucose concentration of one to three weeks and
is an important tool in the monitoring of the diabetic
dog. Fructosamine is especially useful as an indicator
of inadequate glycemic control, and hence of the need
for a BGC or continuous glucose monitoring before ad-
justing the therapy.
The BGC has been used as the gold standard to de-
termine glycemic control for years, but it also has dis-
advantages. The most important drawbacks are the
fact that it is time consuming, subject to hospitalization
related influences and day-to-day variability. A good al-
ternative is teaching the owner to perform the curves
at home in order to get a more reliable image of the
dog’s glycemic status. Continuous glucose monitoring
provides an even better global picture, although hos-
pitalization is often required due to the technical diffi-
culties with the device. Detailed knowledge of the
blood glucose concentration changes throughout the
day, provided by the BGC (performed in the hospital
or at home) or continuous glucose monitoring, is nec-
essary to determine the cause of poor glycemic control
and to make sound adjustments to the insulin therapy.
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